No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HRMY240517P35000
- 2.65
- 0.000.00%
15min DelayClose Apr 30 12:12 ET
0.00High0.00Low
2.65Open2.65Pre Close0 Volume9 Open Interest35.00Strike Price0.00Turnover104.81%IV-2.92%PremiumMay 17, 2024Expiry Date3.30Intrinsic Value100Multiplier9DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.6915Delta0.0664Gamma7.50Leverage Ratio-0.0985Theta-0.0059Rho-5.19Eff Leverage0.0179Vega
Intraday
- 5D
- 1D
News
Some Investors May Be Willing To Look Past Harmony Biosciences Holdings' (NASDAQ:HRMY) Soft Earnings
Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) stock was strong despite it releasing a soft earnings report last week. However, we think the company is showing some signs that things are more pro
Results: Harmony Biosciences Holdings, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Harmony Biosciences Holdings First Quarter 2024 Earnings: EPS Beats Expectations
Harmony Biosciences Outperforms Expectations With Strong Q1 Results and Strategic Acquisition
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q1 2024 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Doing What It Can To Lift Shares
With a price-to-earnings (or "P/E") ratio of 13.6x Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) may be sending bullish signals at the moment, given that almost half of all companies in the United
Comments
$Harmony Biosciences(HRMY.US$
ADDITIONAL
HARMONY BIOSCIENCES HOLDINGS INC: REITERATES 2024 NET PRODUCT REVENUE GUIDANCE OF $700 - $720 MLN
ADDITIONAL
HARMONY BIOSCIENCES HOLDINGS INC: REITERATES 2024 NET PRODUCT REVENUE GUIDANCE OF $700 - $720 MLN
$Harmony Biosciences(HRMY.US$
NEWS
HARMONY BIOSCIENCES HOLDINGS INC: POTENTIAL PAYMENTS OF UP TO $515 MLN IF CERTAIN SALES MILESTONES ARE ACHIEVED
HARMONY BIOSCIENCES Q1 PRETAX PROFIT USD 51.785 MILLION VS. IBES ESTIMATE USD 47.9 MILLION
NEWS
HARMONY BIOSCIENCES HOLDINGS INC: POTENTIAL PAYMENTS OF UP TO $515 MLN IF CERTAIN SALES MILESTONES ARE ACHIEVED
HARMONY BIOSCIENCES Q1 PRETAX PROFIT USD 51.785 MILLION VS. IBES ESTIMATE USD 47.9 MILLION
Harmony Biosciences Holdings' conservative balance sheet and net cash position suggest safe debt management. The company's impressive EBIT growth over the last year aids in handling its debt. Its use of debt is not deemed risky.
$Pfizer(PFE.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$Vera Therapeutics(VERA.US$ Phase 2b
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$Akero Therapeutics(AKRO.US$ Phase 2b
$Spruce Biosciences(SPRB.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Annexon(ANNX.US$ Phase 2a
$Roivant Sciences(ROIV.US$...
$Leap Therapeutics(LPTX.US$ Phase 2
$Vera Therapeutics(VERA.US$ Phase 2b
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$Akero Therapeutics(AKRO.US$ Phase 2b
$Spruce Biosciences(SPRB.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Annexon(ANNX.US$ Phase 2a
$Roivant Sciences(ROIV.US$...
23
Despite expected EPS growth, Harmony Biosciences' low P/E ratio signals bearishness as skeptics question its ability to improve declining earnings, potentially capping its stock price. The P/E and growth outlook mismatch suggests investor concerns about unexpected earnings threats.
Read more